Pharmaceuticals News and Research

RSS

Informative session on TP-drug interactions

AAPS is pleased to present the workshop on Strategies to Address Therapeutic Protein Drug Interactions during Clinical Development. This event will feature a review of pre-clinical tools, test systems, and relevant documented Therapeutic Protein-drug interactions.

4 May 2010

Sucampo Pharmaceuticals presents Phase 2 cobiprostone clinical trial data at DDW 2010

Sucampo Pharmaceuticals, Inc. today presented results of a phase 2 clinical trial of cobiprostone, an investigational drug, for the prevention of gastric ulcers and other gastrointestinal injuries in patients treated with non-steroidal anti-inflammatory drugs (NSAIDs). These data were presented at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, as part of the distinguished abstract plenary session.

4 May 2010

Obese men more likely to have low testosterone than non-obese men: HIM study

Obesity, a condition linked to heart disease and diabetes, now appears to be associated with another health problem, but one that affects men only -- low testosterone levels.

4 May 2010

Broccoli component sulforaphane targets and kills breast cancer stem cells

A compound derived from broccoli could help prevent or treat breast cancer by targeting cancer stem cells -- the small number of cells that fuel a tumor's growth -- according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

4 May 2010

Par Pharmaceutical signs exclusive licensing agreement with Glenmark to market ezetimibe in the U.S.

Par Pharmaceutical Companies, Inc. today announced that its generic division, Par Pharmaceutical, has entered into an exclusive licensing agreement with Glenmark Generics Limited and Glenmark Generics Inc., USA to market ezetimibe 10 mg tablets, the generic version of Merck & Co. Inc.'s Zetia, in the U.S. Zetia is a cholesterol modifying agent with annual U.S. sales of approximately $1.4 billion, according to IMS Health data.

4 May 2010

QIAGEN reports 20% revenue growth in first quarter 2010

QIAGEN N.V. today announced the results of operations for its quarter ended March 31, 2010. Net sales were at the high end of, and adjusted earnings per share for the first quarter 2010 exceeded the guidance provided by the Company on February 9, 2010.

From QIAGEN Manchester Limited 4 May 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2010.

4 May 2010

Fate of the unused swine flu vaccines

The United States Government in an announcement on Monday revealed that the U.S. still has 71 million doses of unused H1N1 swine flu vaccine but there is still time left before it is wasted. They have urged the providers to keep the vaccines and continue to supply them to people until pharmaceutical manufacturers start distributing seasonal vaccine for the coming influenza season in the autumn.

4 May 2010

Boost for biologics manufacturing in Australia

AusBiotech has welcomed the news that Australia’s first major contract manufacturing facility for biologic medicines has secured backing and is set to be built in Queensland by 2012.

3 May 2010

WHO, UNICEF issue guide, call for more research into medicines for children

Along with the release of a WHO-UNICEF guide on medicines for children, the U.N. agencies on Friday said the guide "exposed dangerous shortfalls" in medicines designed for children and called for more research into treating children, Reuters reports. "While effective medicines exist to fight disease and treat life-threatening conditions like malnutrition, formulations suitable for children are often difficult to source," Francisco Blanco, UNICEF's chief of medicines and nutrition, said, according to the news service.

3 May 2010

FDA issues advisory on prostate cancer drugs

Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several studies by the U.S. Food and Drug Administration.

3 May 2010

NOXXON Pharma completes first-in-human clinical trial with Spiegelmer NOX-A12

NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful completion of the first-in-human clinical trial with Spiegelmer® NOX-A12.

3 May 2010

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced interim study results that showed its doxorubicin prodrug INNO-206 demonstrated statistically significant anti-tumor activity in human myeloma tumor cells growing in immune-deficient mice compared to a control group, while exhibiting significantly less toxicity than doxorubicin even though INNO-206 was administered at much higher doses.

3 May 2010

Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting

Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that Ryo Kubota, M.D., Ph.D., Acucela's chairman, president and chief executive officer, has been invited to participate in Retina International's annual Scientific & Medical Advisory Board meeting being held in Fort Lauderdale, Florida on May 3, 2010.

3 May 2010

Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced an amendment to its 2005 collaboration agreement with AstraZeneca expanding the TC-5619 development program. In addition to the current development of TC-5619 in cognitive dysfunction in schizophrenia (CDS), the amended terms provide for parallel development in attention deficit/hyperactivity disorder (ADHD) and potentially Alzheimer's disease.

3 May 2010

BioTime acquires ES Cell International

BioTime, Inc., a biotechnology company that develops and markets products in the field of human stem cells and regenerative medicine, today announced that it has completed its acquisition of the Singapore company ES Cell International Pte Ltd.

3 May 2010

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

3 May 2010

Alnylam Pharmaceuticals announces EPO intent to grant notification for patent series covering RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has issued a notification of an intent to grant for the "Manoharan II" patent series (EP Application No 04 718 537), titled "Therapeutic Compositions." The new patent includes 16 claims covering compositions and methods, including pharmaceutical compositions, for chemically modified siRNAs containing phosphorothioate and 2′-O-alkyl modifications without any siRNA length restrictions.

3 May 2010

Penwest Pharmaceuticals reports net income of $3.9 million for first-quarter 2010

Penwest Pharmaceuticals Co. today announced its financial results for the first quarter ended March 31, 2010. Compared with the first quarter of 2009, first quarter 2010 revenues increased sharply to $8.8 million, and operating expenses decreased by 20%. The Company had net income of $0.12 per share for the first quarter of 2010.

3 May 2010

AVANIR Pharmaceuticals reports net loss of $6.4 million for second-quarter fiscal 2010

AVANIR Pharmaceuticals, Inc. today reported unaudited financial results for the three and six months ended March 31, 2010.

3 May 2010

Pharmaceuticals News and Research

Informative session on TP-drug interactions

Sucampo Pharmaceuticals presents Phase 2 cobiprostone clinical trial data at DDW 2010

Obese men more likely to have low testosterone than non-obese men: HIM study

Broccoli component sulforaphane targets and kills breast cancer stem cells

Par Pharmaceutical signs exclusive licensing agreement with Glenmark to market ezetimibe in the U.S.

QIAGEN reports 20% revenue growth in first quarter 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Fate of the unused swine flu vaccines

Boost for biologics manufacturing in Australia

WHO, UNICEF issue guide, call for more research into medicines for children

FDA issues advisory on prostate cancer drugs

NOXXON Pharma completes first-in-human clinical trial with Spiegelmer NOX-A12

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting

Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease

BioTime acquires ES Cell International

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

Alnylam Pharmaceuticals announces EPO intent to grant notification for patent series covering RNAi therapeutics

Penwest Pharmaceuticals reports net income of $3.9 million for first-quarter 2010

AVANIR Pharmaceuticals reports net loss of $6.4 million for second-quarter fiscal 2010

Pittcon Highlights: Pharmaceutical & Biologic eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News